Wagner R, Modrow S, Böltz T, Fliessbach H, Niedrig M, von Brunn A, Wolf H
Max von Pettenkofer Institute, University of Munich, Federal Republic of Germany.
Arch Virol. 1992;127(1-4):139-52. doi: 10.1007/BF01309580.
To reduce the opportunities for human immunodeficiency virus type 1 (HIV-1) to evade vaccine induced immunity, the development of subunit vaccines must focus on the characterization of immunogenic epitopes, which are major targets for the immune system. The most dominant site for elicitation of neutralising immune response is located on the external envelope glycoprotein gp120 within the third variable domain (V3). To overcome virus type specificity of antibodies directed to the V3-domain we designed a 36 amino acids long gp120/V3-consensus peptide (V3-C36) based on published biological data and sequence comparisons of various HIV-1 virus isolates. This peptide contains a conserved core sequence which is suggested to form a surface-exposed beta-turn. This peptide also includes T-cell epitopes defined in mice and humans, an ADCC-epitope and two highly conserved cysteine residues which were oxidized to form a cystine derivate, thus allowing correct peptide folding. In ELISA-tests, this peptide reacts with at least 90% of randomly selected sera of European and African patients infected with HIV-1 and is recognized by three different HIV-1/V3 "type-specific" antisera (MN, RF, IIIB-strain). Using this peptide as immunogen in rabbits, antisera could be raised with highly cross-reactive and HIV-1/IIIB strain neutralizing properties. Moreover, HTLV/HIV-1/IIIB specific cytotoxic T-lymphocytes (CTLs) of BALB/c mice infected with a gp120 recombinant vaccinia virus recognized the central 16- and 12-mer peptides of the V3-C36 consensus peptide in cytolytic assays, indicating perfect compatibility of the consensus peptide with the IIIB-primed CTLs. The DNA-sequence encoding the V3-consensus loop region might be an important component in newly designed recombinant subunit vaccines. In addition, due to its broad serological reactivity, the V3-consensus peptide might play an important role in special diagnostic purposes.
为减少人类免疫缺陷病毒1型(HIV-1)逃避疫苗诱导免疫的机会,亚单位疫苗的研发必须聚焦于免疫原性表位的特性分析,这些表位是免疫系统的主要靶点。诱导中和免疫反应的最主要位点位于第三个可变区(V3)内的外膜糖蛋白gp120上。为克服针对V3结构域抗体的病毒类型特异性,我们基于已发表的生物学数据和各种HIV-1病毒分离株的序列比较,设计了一种36个氨基酸长的gp120/V3共有肽(V3-C36)。该肽包含一个保守的核心序列,据推测可形成一个表面暴露的β-转角。此肽还包括在小鼠和人类中确定的T细胞表位、一个ADCC表位以及两个高度保守的半胱氨酸残基,它们被氧化形成胱氨酸衍生物,从而使肽能正确折叠。在ELISA试验中,该肽与至少90%随机选取的感染HIV-1的欧洲和非洲患者血清发生反应,并被三种不同的HIV-1/V3“型特异性”抗血清(MN、RF、IIIB株)识别。用该肽作为免疫原免疫兔子,可产生具有高度交叉反应性和HIV-1/IIIB株中和特性的抗血清。此外,感染gp120重组痘苗病毒的BALB/c小鼠的HTLV/HIV-1/IIIB特异性细胞毒性T淋巴细胞(CTL)在溶细胞试验中识别V3-C36共有肽的中央16肽和12肽,表明共有肽与IIIB预激发的CTL具有完美的兼容性。编码V3共有环区域的DNA序列可能是新设计的重组亚单位疫苗的重要组成部分。此外,由于其广泛的血清学反应性,V3共有肽可能在特殊诊断用途中发挥重要作用。